DrugPatentWatch Database Preview
Ozanimod hydrochloride - Generic Drug Details
» See Plans and Pricing
What are the generic drug sources for ozanimod hydrochloride and what is the scope of freedom to operate?
Ozanimod hydrochloride
is the generic ingredient in one branded drug marketed by Celgene Intl and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Ozanimod hydrochloride has twenty-seven patent family members in twenty countries.
One supplier is listed for this compound.
Summary for ozanimod hydrochloride
| International Patents: | 27 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Clinical Trials: | 16 |
| DailyMed Link: | ozanimod hydrochloride at DailyMed |
Recent Clinical Trials for ozanimod hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Bristol-Myers Squibb | Phase 2 |
| François Lellouche | Phase 2 |
| Celgene | Phase 2/Phase 3 |
US Patents and Regulatory Information for ozanimod hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celgene Intl | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-003 | Mar 25, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Celgene Intl | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-001 | Mar 25, 2020 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Celgene Intl | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-003 | Mar 25, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Celgene Intl | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-002 | Mar 25, 2020 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Celgene Intl | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-001 | Mar 25, 2020 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Celgene Intl | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-003 | Mar 25, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ozanimod hydrochloride
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20110010777 | Start Trial |
| South Korea | 20150064245 | Start Trial |
| Denmark | 2291080 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2009151529 | Start Trial |
| Mexico | 2010012461 | Start Trial |
| Portugal | 2291080 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
